Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Outlook Therapeutics Inc (OTLKW)

Outlook Therapeutics Inc (OTLKW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones Globe Newswire - Wed Aug 10, 2022

Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference Globe Newswire - Thu Aug 4, 2022

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note Globe Newswire - Tue Jul 5, 2022

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010 Globe Newswire - Tue Jun 14, 2022

Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD Globe Newswire - Tue May 31, 2022

ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference Globe Newswire - Wed May 18, 2022

ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update Globe Newswire - Fri May 13, 2022

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook Therapeutics to Participate in Retina World Congress 2022 Globe Newswire - Tue May 10, 2022

ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight Globe Newswire - Mon May 9, 2022

Live moderated video webcast on Wednesday, May 11th at 1:00 PM ET...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)
BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics Globe Newswire - Fri Apr 22, 2022

SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical...

OTLKW : 0.03 (-1.96%)
OTLK : 7.33 (-1.35%)

Barchart Exclusives

Is It Too Late to Buy This Energy Dividend Stock at New Highs? Barchart - Thu May 16, 6:30PM CDT
Here's a closer look at whether Constellation Energy's recent surge to record highs presents a lucrative opportunity to buy into the bullish momentum, or whether investors should practice caution at the current valuation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot